Teva Pharmaceutical Industries (TEVA) Reports Q3 Earnings: What Key Metrics Have to Say

Teva Pharmaceutical Industries Ltd. (TEVA) reported $4.33 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 12.5%. EPS of $0.69 for the same period compares to $0.60 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $4.08 billion, representing a surprise of +6.12%. The company delivered an EPS surprise of +6.15%, with the consensus EPS estimate being $0.65.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Teva Pharmaceutical Industries performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Geographic Revenue- International Markets: $613 million versus $615.37 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +26.4% change. Geographic Revenue- United States: $2.23 billion versus the four-analyst average estimate of $2.06 billion. The reported number represents a year-over-year change of +11.1%. Geographic Revenue- United States- COPAXONE: $69 million versus $49.93 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -33% change. Geographic Revenue- United States- BENDEKA / TREANDA: $40 million versus $38.21 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -29.8% change. Geographic Revenue- United States- AUSTEDO: $435 million versus the four-analyst average estimate of $436.83 million. The reported number represents a year-over-year change of +28.3%. Geographic Revenue- United States- Anda: $380 million versus the four-analyst average estimate of $351.57 million. The reported number represents a year-over-year change of +3.5%. Geographic Revenue- Europe- COPAXONE: $53 million versus the four-analyst average estimate of $47.56 million. The reported number represents a year-over-year change of -3.6%. Geographic Revenue- Europe- Respiratory products: $60 million versus the four-analyst average estimate of $57.37 million. The reported number represents a year-over-year change of -1.6%. Geographic Revenue- International Markets- Generic products: $477 million versus the four-analyst average estimate of $497.41 million. The reported number represents a year-over-year change of +25.2%. Geographic Revenue- International Markets- COPAXONE: $13 million versus $12.27 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +30% change. Geographic Revenue- United States- AJOVY: $58 million compared to the $56.34 million average estimate based on four analysts. The reported number represents a change of -4.9% year over year. Geographic Revenue- Europe- Generic products: $973 million versus the four-analyst average estimate of $930.59 million. The reported number represents a year-over-year change of +9.8%. View all Key Company Metrics for Teva Pharmaceutical Industries here>>>Shares of Teva Pharmaceutical Industries have returned +7.1% over the past month versus the Zacks S&P 500 composite's +0.7% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.Zacks Names #1 Semiconductor StockIt's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks